
    
      The aim of this pilot study is to assess the safety and tolerability profile of 2 doses of
      EHT 0202 (40 mg and 80 mg b.i.d) versus placebo in addition to a treatment with
      acetylcholinesterase inhibitor and its exploratory efficacy on cognition, behavior,
      activities of daily living, caregiver's burden and patient's global assessment, during a
      3-month treatment period.
    
  